Article Details
Retrieved on: 2024-01-18 21:16:53
Tags for this article:
Click the tags to see associated articles and topics
Summary
AEON Biopharma reports positive Phase 2 results for ABP-450, demonstrating safety and effectiveness in treating cervical dystonia and presents pre-clinical data on potential PTSD treatment, highlighting its focus on botulinum toxin research. Relevant to biopharma, botulism, and bacterial toxins.
Article found on: www.globenewswire.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here